Twelve-year follow-up study of hepatitis B immunization of Senegalese infants.

Abstract

Numerous studies have documented the efficacy and safety of plasma-derived and recombinant hepatitis B vaccines. However, little is known about the long-term protection of hepatitis B vaccine, when anti-HBs declines to low or undetectable levels. This study reports results from a 9-12-year period follow up of infants immunized against hepatitis B in Senegal. At the end of the follow-up period anti-HBs were detected in 81% of children who received a booster dose at school age and in 68% of those who did not. HBsAg was detected in 19% of infants from the control group compared to only 2% of immunized infants, corresponding to a protective efficacy of 88%. The results show that long-term protection against HBsAg carriage of hepatitis B vaccination is very high and that a booster dose at school age does not significantly increase this protection.

• Authors: P Coursaget, D Leboulleux, M Soumare, P le Cann, B Yvonnet, J P Chiron, A M Coll-Seck, I Diop-Mar
• Journal: Journal of hepatology (J Hepatol) Vol. 21 Issue 2 Pg. 250-4 (Aug 1994) ISSN: 0168-8278 [Print] Netherlands
• PMID: 7989718 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Hepatitis B Surface Antigens
• Hepatitis B Vaccines

Topics

• Child
• Child, Preschool
• Follow-Up Studies
• Hepatitis B (epidemiology, prevention & control)
• Hepatitis B Surface Antigens (analysis, blood)
• Hepatitis B Vaccines (adverse effects, standards)
• Humans
• Infant
• Infant, Newborn
• Senegal (epidemiology)